Home

  • ABAX34.43-0.78 - -2.32%
  • HSKA13.44-0.18 - -1.43%
  • IDXX85.80-2.02 - -2.40%
  • MWIV94.81-1.05 - -1.14%
  • PETS12.15+0.34 - +3.03%
  • WOOF21.34-0.22 - -1.04%
  • PDCO33.65-0.54 - -1.65%
  • MRK37.87-0.209 - -0.55%
  • PFE22.60+0.01 - +0.04%
  • ABT62.00-0.66 - -1.06%
  • HSIC76.01-0.69 - -0.94%
  • ^IXIC2778.79-34.90 - -1.24%
  • ^GSPC1295.22-9.64 - -0.74%
  • ^FTSE5267.62-70.76 - -1.33%
  • ^N2258611.310 - 0.00%

WELCOME TO VeterinaryInvesting.com

Our mission is to stimulate investment and innovation in Veterinary Medicine.
We’ll supply the site and relevant News Briefs, but the discussions are up to you!
How can you get involved?

Polls – please vote in our weekly poll on the right side of the homepage.  Questions will be relevant to Veterinary business, and hopefully we can use them to spot trends.  Suggestions certainly welcome!

Forums – topics may be started at any time relating to Veterinary Medicine and innovation and investment.  Example topics are…..
“What emerging technologies may shape the future of Veterinary Medicine?”
“What investment vehicles have you used to invest in Veterinary Medicine?”

Business Opportunities – Looking for a business partner, investors, practices to buy/sell, a place to invest????  You’ve come to the right place!
Twitter: @VetMedInvesting   Please sign up for our newsletter! –>>

Featured Discussion:  Should all Veterinarians be required to specialize?

Does It Work?

Will It Work?

Top Stories
CytoDyn Plans to Move Forward with CytoFeline
May 16th, 2012  Biotechnology company CytoDyn Inc. (OTCQB:CYDY), which focuses on development of antibodies, has announced that it has produced enough CytoFeline to proceed with the next stage of the antibody’s development.  CytoFeline is a monoclonal antibody developed to treat Feline Immunodeficiency Virus (FIV).  CytoDyn has selected Colorado State University to continue research and lead efficacy trials of CytoFeline.

IDEXX To Offer Allergy Testing
May 14th, 2012  IDEXX Laboratories (IDXX) has announced that it has entered into an agreement with GREER, a provider of immunotherapy products for humans and animals.  Allergy testing will now be available on blood samples sent to IDEXX and immunotherapy will be developed by GREER.  The service will be available to canine, feline and equine patients.

Heska Reports Q1 2012 Earnings
May 10th, 2012  Heska Corporation (HSKA) reported Q1 earnings of $0.11/share, which is down from Q1 2011 which came in at $0.17/share.  Q1 revenue came in at $19.2 million versus $19.5 million a year ago.  Heska does report that gross margin increased 400 basis points over a year ago to 46.5%.

MWI Reports Strong Q2
May 3rd, 2012  MWI Veterinary Supply (MWIV) reported Q2 2012 EPS of $1.04, beating analyst’s consensus of $0.96/share.  Revenue was up 38.3% to to $507.2 million, easily beating estimates of $465 million.  MWIV also raised guidance for 2012 to revenues of $2.0-20.25 billion from $1.90-1.95 billion.

VeterinaryInvesting Blog: Can Pet Insurance Save Veterinary Medicine?
Pet Health Insurance has become more popular with pet owners over the past decade, but what role can it play in the future of Veterinary Medicine?  With a soft economy and the rising cost of providing veterinary care, many practices are finding patient visits and subsequent revenues down.  Pet insurance may just be one important part needed to improve this situation….more


Comments are closed.